For many people living with inflammatory bowel disease (IBD), a routine flu jab or travel vaccine suddenly raises new questions once immune-suppressing medication becomes part of treatment. Will the vaccine still work? Is it even safe? These are reasonable concerns, and the answers depend largely on which medication is being used and what type of vaccine is being considered.
What is immune suppression in IBD?
Crohn’s disease and ulcerative colitis, the two main forms of IBD, are driven by an immune system that reacts inappropriately to the gut lining, causing ongoing inflammation. Many effective treatments work by calming this overactive immune response, using medications broadly grouped as immunosuppressants (drugs that reduce immune activity) and biologics (medicines made from living cells that target specific parts of the immune system). While this dampening effect helps control gut inflammation, it can also reduce the body’s ability to respond to infections and, in some cases, to vaccines.
Why vaccination matters for gut inflammation
The gut lining and the immune system are closely linked, and a body already managing inflammation has less reserve to deal with additional infections. People on immune-suppressing therapy are more vulnerable to certain infections, and some infections can even trigger flares or complicate treatment. Vaccination reduces this risk before it becomes a problem, making it an important, though often overlooked, part of long-term IBD management rather than a separate issue from gut health.
Key mechanisms and clinical context
Live versus inactivated vaccines
Vaccines fall into two broad categories. Live vaccines contain a weakened version of the actual virus (examples include the MMR, yellow fever, and shingles vaccines Zostavax and the nasal flu spray). Inactivated vaccines contain a killed virus, a fragment of it, or genetic instructions for the body to build a harmless protein, as with mRNA vaccines. Live vaccines are generally avoided during significant immune suppression because the weakened virus could, in rare cases, cause illness. Inactivated vaccines are considered safe throughout treatment.
Timing around starting treatment
Ideally, any live vaccines and general catch-up immunisations are reviewed and given before starting immunosuppressants or biologics, while the immune system is still working at full strength. This is why gastroenterology teams often check vaccination history at diagnosis, well before medication decisions are made.
Reduced vaccine response on treatment
Some immune-suppressing medications, particularly corticosteroids at higher doses, thiopurines (such as azathioprine), and combination therapy with biologics, can blunt the antibody response to vaccines. This does not mean vaccination is pointless, it usually still offers meaningful protection, but the response may be somewhat weaker than in someone without IBD. This is one reason annual flu and periodic pneumococcal (a bacterium that can cause pneumonia) vaccination are particularly encouraged.
Biologics and specific risk patterns
Anti-TNF (tumour necrosis factor, an inflammatory signalling protein) biologics such as infliximab and adalimumab are linked with a modestly increased risk of certain infections, including shingles, which has made the non-live shingles vaccine (Shingrix) a specific recommendation for eligible patients. JAK inhibitors (a newer tablet-based biologic class) carry a similarly recognised shingles risk, reinforcing the same advice.
Family members and household vaccination
Because live vaccines cannot always be given directly to someone on strong immune suppression, keeping household members and close contacts up to date with their own vaccinations, including live ones like MMR, indirectly protects the patient by reducing circulating infection risk at home.
It is worth remembering that symptoms such as fatigue, joint aches, or mild fever after vaccination do not necessarily mean a flare is starting, and gut symptoms should always be discussed with the IBD team rather than assumed to be vaccine-related. Vaccination decisions should always be made in partnership with a gastroenterologist or IBD nurse, who can weigh up current medication, disease activity, and individual risk factors.
Practical takeaways
- Ask the IBD team for a vaccination review at diagnosis, ideally before starting immunosuppressants or biologics.
- Have live vaccines completed before immune-suppressing treatment begins, where possible.
- Get an annual flu vaccine and ask about pneumococcal and shingles vaccination if eligible.
- Check vaccination status again before international travel, as some destinations require live vaccines.
- Encourage household members to stay up to date with their own vaccinations.
- Report any new symptoms after vaccination to the IBD team rather than self-diagnosing a flare.
Conclusion
Vaccination remains one of the simplest and most effective ways to reduce infection risk for people on immune-suppressing IBD treatment, and it works alongside medical care rather than instead of it. The key distinction to remember is between live and inactivated vaccines, and the importance of timing vaccinations around treatment changes. With planning and regular communication with the IBD team, most vaccines can be safely and effectively incorporated into long-term disease management. Stability, both in gut inflammation and overall health, is best supported by keeping vaccination status current rather than reactive.
References
- Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443-468. doi:10.1016/j.crohns.2013.12.013
- Kucharzik T, Ellul P, Poullenot G, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):879-913. doi:10.1093/ecco-jcc/jjab029
- Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834-1840. doi:10.1111/j.1572-0241.2006.00646.x
- Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105(6):1231-1238. doi:10.1038/ajg.2009.733
- Caldera F, Hillman L, Saha S, et al. Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial. Inflamm Bowel Dis. 2020;26(4):593-602. doi:10.1093/ibd/izz164
- Kappelman MD, Weaver KN, Boccieri M, et al. Humoral immune response to messenger RNA COVID-19 vaccines among patients with inflammatory bowel disease. Gastroenterology. 2021;161(4):1340-1343. doi:10.1053/j.gastro.2021.06.016
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.